Glimperide, Metformin & Pioglitazone Combination (Extended Release)

Get a Price/Quote

Glimperide, Metformin & Pioglitazone Combination (Extended Release) Specification

Drug Type
Specific Drug

Ingredients
Glimepiride 1 mg + Metformin 500 mg + Pioglitazone 15 mg (ER) Glimepiride 2 mg + Metformin 500 mg + Pioglitazone 15 mg (ER)

Physical Form
Tablets

Function
Other

Recommended For
Management of Type 2 diabetes (NIDDM)

Suitable For
Adults, Aged Person

Glimperide, Metformin & Pioglitazone Combination (Extended Release) Trade Information

Payment Terms
Western Union, Cash in Advance (CID), Cheque, Cash Advance (CA)

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
ALu-Alu,10*10 Pack

Main Export Market(s)
Western Europe, Australia, Eastern Europe, Middle East, South America, Asia, Central America, North America, Africa

Main Domestic Market
All India

Certifications
WHO-GMP

About Glimperide, Metformin & Pioglitazone Combination (Extended Release)

Glimperide, Metformin & Pioglitazone Combination (Extended Release) Tablets are specifically designed for effective management of Type 2 Diabetes Mellitus (NIDDM). Available in two formulations - Glimepiride 1 mg + Metformin 500 mg + Pioglitazone 15 mg (ER) and Glimepiride 2 mg + Metformin 500 mg + Pioglitazone 15 mg (ER) - these tablets combine three active ingredients that work synergistically to help control blood sugar levels in adults and older individuals. Glimepiride stimulates the pancreas to produce insulin, Metformin decreases glucose production in the liver, and Pioglitazone improves insulin sensitivity. The extended-release formulation ensures a sustained effect throughout the day for better glycemic control. These tablets are recommended for diabetic patients seeking reliable and comprehensive management of their condition.